Nature Communications (Sep 2019)
Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease
- Edmund C. Lee,
- Tania Valencia,
- Charles Allerson,
- Annelie Schairer,
- Andrea Flaten,
- Matanel Yheskel,
- Kara Kersjes,
- Jian Li,
- Sole Gatto,
- Mandeep Takhar,
- Steven Lockton,
- Adam Pavlicek,
- Michael Kim,
- Tiffany Chu,
- Randy Soriano,
- Scott Davis,
- John R. Androsavich,
- Salma Sarwary,
- Tate Owen,
- Julia Kaplan,
- Kai Liu,
- Graham Jang,
- Steven Neben,
- Philip Bentley,
- Timothy Wright,
- Vishal Patel
Affiliations
- Edmund C. Lee
- Regulus Therapeutics Inc.
- Tania Valencia
- Regulus Therapeutics Inc.
- Charles Allerson
- Regulus Therapeutics Inc.
- Annelie Schairer
- Regulus Therapeutics Inc.
- Andrea Flaten
- Department of Internal Medicine and Division of Nephrology, University of Texas Southwestern Medical Center
- Matanel Yheskel
- Department of Internal Medicine and Division of Nephrology, University of Texas Southwestern Medical Center
- Kara Kersjes
- Regulus Therapeutics Inc.
- Jian Li
- Regulus Therapeutics Inc.
- Sole Gatto
- Regulus Therapeutics Inc.
- Mandeep Takhar
- Regulus Therapeutics Inc.
- Steven Lockton
- Regulus Therapeutics Inc.
- Adam Pavlicek
- Regulus Therapeutics Inc.
- Michael Kim
- Regulus Therapeutics Inc.
- Tiffany Chu
- Regulus Therapeutics Inc.
- Randy Soriano
- Regulus Therapeutics Inc.
- Scott Davis
- Regulus Therapeutics Inc.
- John R. Androsavich
- Regulus Therapeutics Inc.
- Salma Sarwary
- Regulus Therapeutics Inc.
- Tate Owen
- Regulus Therapeutics Inc.
- Julia Kaplan
- Regulus Therapeutics Inc.
- Kai Liu
- Regulus Therapeutics Inc.
- Graham Jang
- Regulus Therapeutics Inc.
- Steven Neben
- Regulus Therapeutics Inc.
- Philip Bentley
- Regulus Therapeutics Inc.
- Timothy Wright
- Regulus Therapeutics Inc.
- Vishal Patel
- Department of Internal Medicine and Division of Nephrology, University of Texas Southwestern Medical Center
- DOI
- https://doi.org/10.1038/s41467-019-11918-y
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 14
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a leading genetic cause of end-stage renal disease with limited treatment options. Here the authors discover and characterize a microRNA inhibitor as a potential treatment for ADPKD.
